RESUMO
PURPOSE/OBJECTIVES: To explore bone metastasis using Roy's Adaptation Model as a conceptual framework. DATA SOURCES: Published articles, conference abstracts, recent texts, and prescribing information. DATA SYNTHESIS: Bone metastasis has a significant impact on the patient's ability to maintain physical and psychosocial functions. Primary (self), secondary (family and occupation), and tertiary (community) roles, as identified by the Roy Adaptation Model, may be impaired as a result of bone metastasis. Patient education is a nursing intervention that frequently is used, as it allows an individual to interpret an aversive event and take action, thus promoting adaptation to illness. Medications for the underlying disease, bone metastasis, pain, and other symptoms warrant consideration. Active interventions, such as relaxation therapy, guided imagery, music, meditation, and therapeutic touch, also promote adaptation. CONCLUSIONS: Bone is a common and potentially debilitating site of metastasis. The presence of bone metastasis indicates progressive and, almost always, incurable disease. Patient adaptation can be enhanced through the proper use of palliative therapies and other nursing measures. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses can assist in the physical and psychosocial adaptation of patients with bone metastasis through assessment, patient education, and symptom management.
Assuntos
Adaptação Psicológica , Neoplasias Ósseas/psicologia , Neoplasias Ósseas/secundário , Modelos Psicológicos , Dor/prevenção & controle , Neoplasias Ósseas/fisiopatologia , Humanos , Enfermagem Oncológica/métodos , Dor/etiologia , Dor/fisiopatologia , Dor/psicologia , Papel (figurativo) , Autoimagem , Apoio SocialRESUMO
Bisphosphonates are potent inhibitors of bone resorption and provide a therapeutic benefit for patients with bone metastases. Zoledronic acid is a highly potent, nitrogen-containing bisphosphonate. In the present trial, we assessed the safety and tolerability of increasing doses of zoledronic acid and its effects on urinary markers of bone resorption in cancer patients with bone metastases. Fifty-nine cancer patients with bone metastases were enrolled sequentially into one of 8 treatment groups in the core protocol. Each patient received a 5-min i.v. infusion of 0.1, 0.2, 0.4, 0.8, 1.5, 2, 4, or 8 mg zoledronic acid monthly for 3 months. Patients were monitored for clinical findings, adverse events, electrocardiograms, markers of bone resorption, as well as routine hematology, blood chemistries, and urinalysis. Thirty patients who demonstrated a radiographic response to treatment or stable disease in the core protocol were enrolled in a humanitarian extension protocol and continued to receive monthly infusions. Zoledronic acid was well tolerated at all dose levels. Adverse events reported by >10% of patients included skeletal pain, nausea, fatigue, upper respiratory tract infection, constipation, headache, diarrhea, and fever. Three patients in the core protocol and one patient in the extension protocol experienced grade 3 skeletal pain, "flu-like" symptoms, or hypophosphatemia, which were possibly related to treatment; all recovered completely. Adverse events were reported with similar frequency across all of the dosage groups. Zoledronic acid resulted in sustained, dose-dependent decreases in urinary markers of bone resorption. Zoledronic acid was safe and well tolerated and demonstrated potent inhibition of bone resorption.
Assuntos
Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/secundário , Difosfonatos/efeitos adversos , Difosfonatos/uso terapêutico , Imidazóis/efeitos adversos , Imidazóis/uso terapêutico , Metástase Neoplásica/tratamento farmacológico , Adulto , Idoso , Reabsorção Óssea , Creatinina/urina , Difosfonatos/toxicidade , Relação Dose-Resposta a Droga , Feminino , Humanos , Imidazóis/toxicidade , Masculino , Pessoa de Meia-Idade , Neoplasias/patologia , Fatores de Tempo , Ácido ZoledrônicoRESUMO
We evaluated the effects of the addition of escalating doses of tumor necrosis factor (TNF) to two fixed doses and schedules of a combination of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) to determine the maximum tolerated dose of this three-cytokine combination and its feasibility as an outpatient regimen. Eighteen patients with metastatic cancer were enrolled. Each course consisted of 3 consecutive weeks of treatment with IFN-alpha 9 x 10(6) IU/m2/day intramuscularly (i.m.) or subcutaneously (s.c.) days 1, 3, and 5 each week for 3 weeks plus IL-2 continuous infusion 1 x 10(6) IU/m2/day (group A) or 3 x 10(6) IU/m2/day (group B) days 1-5 each week for 3 weeks. TNF was administered only during the first week of each course intravenously (i.v.) for 2 h on days 1-5. The dose of TNF was escalated (40, 80, 120 micrograms/m2) in cohorts of 3 patients. The most common side effects were fever, chills, and fatigue in all patients. Grade 3-4 toxicity included anemia (3 patients), thrombocytopenia (1 patients), arrhythmia (2 patients), pulmonary edema (3 patients),- and weight loss (1 patient). Five patients withdrew from study due to toxicity. The combination of the three cytokines is feasible as an outpatient regimen in one of the following combinations: (a) TNF 80 micrograms/m2/day as 2-h infusion on days 1-5 + IL-2 1 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks, or (b) TNF 40 micrograms/m2/day as a 2-h infusion on days 1-5 + IL-2 3 x 10(6) IU/m2/day continuous infusion on days 1-5 for 3 weeks + IFN-alpha 9 x 10(6) IU/m2/day s.c. or i.m. on days 1, 3, and 5 for 3 weeks.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Interferon-alfa/uso terapêutico , Interleucina-2/uso terapêutico , Neoplasias/terapia , Fator de Necrose Tumoral alfa/uso terapêutico , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/efeitos adversos , Adulto , Idoso , Assistência Ambulatorial , Anemia/etiologia , Arritmias Cardíacas/etiologia , Estudos de Coortes , Fadiga/etiologia , Estudos de Viabilidade , Feminino , Febre/etiologia , Humanos , Infusões Intravenosas , Injeções Intramusculares , Injeções Subcutâneas , Interferon-alfa/administração & dosagem , Interferon-alfa/efeitos adversos , Interleucina-2/administração & dosagem , Interleucina-2/efeitos adversos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Edema Pulmonar/etiologia , Indução de Remissão , Estremecimento/imunologia , Trombocitopenia/etiologia , Fator de Necrose Tumoral alfa/administração & dosagem , Fator de Necrose Tumoral alfa/efeitos adversos , Redução de PesoRESUMO
The combination of interleukin-2 (IL-2) and interferon-alpha-2a (IFN-alpha-2a) has synergistic bioactivity in numerous preclinical model systems. Thirty-nine patients with metastatic renal cell cancer were treated with continuous intravenous infusion IL-2 for 4-5 days plus intramuscular IFN-alpha-2a 2-3 days a week for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Thirty-one of the 39 patients were assessable for response determination. Response rate (six complete+seven partial remissions) was 33.3% for all patients, or 41.9% when the analysis was restricted to the 31 evaluable patients. Three patients were unable to tolerate treatment due to anorexia, weight loss, and severe fatigue. This therapy was relatively well tolerated in the outpatient setting in the other patients despite fever, chills, fatigue, anorexia, and weight loss. There was no correlation of response with site of metastases or bulk of disease.
Assuntos
Carcinoma de Células Renais/secundário , Carcinoma de Células Renais/terapia , Interferon-alfa/uso terapêutico , Interleucina-2/uso terapêutico , Neoplasias Renais/terapia , Adulto , Idoso , Carcinoma de Células Renais/mortalidade , Terapia Combinada , Esquema de Medicação , Sinergismo Farmacológico , Quimioterapia Combinada , Feminino , Humanos , Interferon alfa-2 , Interferon-alfa/administração & dosagem , Interferon-alfa/efeitos adversos , Interleucina-2/administração & dosagem , Interleucina-2/efeitos adversos , Neoplasias Renais/mortalidade , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Resultado do TratamentoRESUMO
Twenty-six patients were treated in this phase I study with the combination of interleukin-2 (IL2) administered as a continuous infusion and interferon alfa-2a (IFN alpha-2a) administered intramuscularly to patients in an outpatient setting. The maximum-tolerated dose of both agents given as outpatient therapy was 2 x 10(6) U/m2 days 1 to 5 of IL2 and 9 x 10(6) U/m2 days 1, 3, and 5 of IFN alpha-2a for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Fatigue was the treatment-limiting toxicity, and serious clinical or laboratory abnormalities occurred infrequently during this study. Patients with colon cancer metastatic to the liver tolerated treatment worse than patients with other tumors. Twelve of the 15 patients with renal cell cancer were assessable for response determinations. Of these 12 patients, three exhibited complete tumor regression, three have had partial objective regression, and three patients experienced stabilization of rapidly progressive disease. This therapy appears to be well tolerated in an outpatient treatment setting and shows significant activity against advanced renal cell cancer.
Assuntos
Interferon-alfa/administração & dosagem , Interleucina-2/administração & dosagem , Neoplasias/terapia , Adulto , Idoso , Assistência Ambulatorial , Carcinoma de Células Renais/terapia , Esquema de Medicação , Avaliação de Medicamentos , Fadiga/etiologia , Feminino , Humanos , Infusões Intravenosas , Injeções Intramusculares , Interferon alfa-2 , Interferon-alfa/efeitos adversos , Interferon-alfa/uso terapêutico , Interleucina-2/efeitos adversos , Interleucina-2/uso terapêutico , Neoplasias Renais/terapia , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Indução de RemissãoRESUMO
Human pancreas contains receptors for estrogens and androgens as well as aromatase activity. FAM chemotherapy was administered to 14 patients with pancreatic cancer (seven at Stage IV). The median survival of these patients was 24.4 +/- 4.8 weeks. FAM chemotherapy plus aminoglutethimide/hydrocortisone (AG/HC) (250 mg bid AG + 20 mg bid HC) was administered to 14 patients (seven at stage IV). The median survival of this group was 17.3 +/- 2.9 weeks (P = 0.74 vs FAM alone). We conclude that addition of AG/HC does not add to the survival of patients with carcinoma of the pancreas treated with chemotherapy.